<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYCLOMYDRIL- cyclopentolate hydrochloride and phenylephrine hydrochloride solution/ drops </strong><br>Alcon Laboratories, Inc.<br></p></div>
<h1>
<span class="Bold"></span>Cyclomydril<span class="Sup">®</span><br>      (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution)       <br>Sterile</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION</h1>
<p class="First">CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is a mydriatic prepared as a sterile topical ophthalmic solution. The active ingredients are represented by the chemical structures:</p>
<div class="Figure"><img alt="
chemical" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8268b70f-3f10-48dd-bb24-baaeb27a1325&amp;name=chemical.jpg"></div>
<p><span class="Bold">Each mL contains: Active: </span>cyclopentolate hydrochloride 0.2%, phenylephrine hydrochloride 1%. <span class="Bold">Preservative: </span>benzalkonium chloride 0.01%. <span class="Bold">Inactives: </span>edetate disodium, boric acid, hydrochloric acid and /or sodium carbonate (to adjust pH), purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY</h1>
<p class="First">Cyclopentolate hydrochloride is an anticholinergic drug and Phenylephrine hydrochloride is an adrenergic drug. This combination induces <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> that is greater than that of either drug alone at its respective concentration. The concentrations of cyclopentolate hydrochloride and phenylephrine hydrochloride have been selected to induce <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> with little accompanying <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>. Heavily pigmented irides may require more doses than lightly pigmented irides.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE</h1>
<p class="First">For the production of <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS</h1>
<p class="First">Do not use in patients with untreated narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or with untreated anatomically narrow angles or where there is <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this preparation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-5"></a><p></p>
<h1>
WARNINGS</h1>
<p class="First">FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. The use of this combination may have an adverse effect on individuals suffering from cardiovascular disease, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, and it may cause CNS disturbances. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate. Observe infants closely for at least 30 minutes.</p>
<p>Mydriatics may produce a transient elevation of intraocular pressure.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="splSectionPrecautions"></a><a name="section-6"></a><p></p>
<h1>
PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-6.1"></a><p></p>
<h2>
General</h2>
<p class="First">The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down's syndrome and in those predisposed to angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. The effect of long-term use of this preparation has not been established, therefore, it should be restricted to short-term use.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-6.2"></a><p></p>
<h2>
Information for Patients</h2>
<p class="First">Do not touch dropper tip to any surface, as this may contaminate the solution. Patient should be advised not to drive or engage in hazardous activities while pupils are dilated. Patient may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="splSectionPrecautionsDrugInteract"></a><a name="section-6.3"></a><p></p>
<h2>
Drug Interactions</h2>
<p class="First">Cyclopentolate may interfere with the ocular anti-hypertensive action of carbachol, pilocarpine, or ophthalmic <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="splSectionPrecautionsCarcinogen"></a><a name="section-6.4"></a><p></p>
<h2>
Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">There have been no long-term studies done using cyclopentolate hydrochloride and/or phenylephrine hydrochloride in animals to evaluate carcinogenic potential.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-6.5"></a><p></p>
<h2>
Pregnancy</h2>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with cyclopentolate hydrochloride and/or phenylephrine hydrochloride. It is also not known whether cyclopentolate hydrochloride and/or phenylephrine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CYCLOMYDRIL® Ophthalmic Solution should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-6.6"></a><p></p>
<h2>
Nursing Mothers</h2>
<p class="First">It is not known whether these drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CYCLOMYDRIL Ophthalmic Solution is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-6.7"></a><p></p>
<h2>
Pediatric Use</h2>
<p class="First">Use of cyclopentolate has been associated with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with <span class="product-label-link" type="condition" conceptid="4300746" conceptname="Spastic paralysis">spastic paralysis</span> or <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span>. These disturbances include <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, incoherent speech, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> as to time and place, and failure to recognize people. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld for four (4) hours after examination. Observe infants closely for at least 30 minutes (See <span class="Bold Underline"><a href="#splSectionWarnings">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-6.8"></a><p></p>
<h2>
Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-7"></a><p></p>
<h1>
ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Ocular: </span>The following ocular adverse experiences have been associated with the use of CYCLOMYDRIL: <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, burning/irritation upon instillation, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">superficial punctate keratitis</span>.</p>
<p><span class="Bold">Non-ocular: </span>Use of cyclopentolate hydrochloride has been associated with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic reactions</span> and behavioral disturbances in children. These disturbances include <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, incoherent speech, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> as to time and place, and failure to recognize people. This drug produces reactions similar to those of other adrenergic and anticholinergic drugs; however, the central nervous system manifestations as noted above are most common. Other manifestations of adrenergic and anticholinergic topical ophthalmic drugs include <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, vasodilation, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, medullary <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-8"></a><p></p>
<h1>
OVERDOSAGE</h1>
<p class="First">Excessive dosage may produce behavioral disturbances, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, elevated intraocular pressure, vasodilation, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Patients exhibiting signs of overdosage should receive supportive care and monitoring.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-9"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION</h1>
<p class="First">Instill one drop in each eye every five to ten minutes. To minimize systemic absorption, apply pressure over the nasolacrimal sac for two to three minutes following instillation. Observe infants closely for at least 30 minutes.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-10"></a><p></p>
<h1>
HOW SUPPLIED</h1>
<p class="First">2 mL and 5 mL in plastic DROP-TAINER® dispensers.</p>
<p>2 mL NDC 0065-0359-02</p>
<p>5 mL NDC 0065-0359-05</p>
<p><span class="Bold">Storage: </span>Store at 8° - 25°C (46° - 77°F).</p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="splSection1"></a><a name="section-11"></a><p></p>
<p class="First">Revised: July 2013</p>
<p>©2004, 2013 Novartis</p>
<p><span class="Bold">9009877-0713</span></p>
<p><span class="Bold">ALCON LABORATORIES, INC.</span></p>
<p>6201 South Freeway <br>Fort Worth, Texas 76134-2099 <br>a Novartis company</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-12"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC </span>0065-0359-05<br><br><span class="Bold">Alcon</span><br><span class="Bold">Cyclomydril<span class="Sup">®</span><br></span>(cyclopentolate hydrochloride, phenylephrine hydrochloride ophthalmic solution)<br><br><span class="Bold">5 mL Sterile<br></span><br><span class="Bold">Rx Only<br></span><br>Sterile Ophthalmic Solution<br><br><span class="Bold">USUAL DOSAGE: </span>Instill one drop in each eye every five to ten minutes. Read enclosed insert.<br><br><span class="Bold">FOR TOPICAL OPHTHALMIC USE ONLY<br></span><br><span class="Bold">WARNING: </span>Do not touch dropper tip to any surface as this may contaminate the solution.<br><br><span class="Bold">INGREDIENTS: Each mL contains: Active: </span>cyclopentolate hydrochloride 0.2%, phenylephrine hydrochloride 1%. <span class="Bold">Preservative: </span>benzalkonium chloride 0.01%. <span class="Bold">Inactives: </span>edetate disodium, boric acid, hydrochloric acid and/or sodium carbonate (to adjust pH), purified water.<br><br><span class="Bold">STORAGE: </span>Store at 8°-25° C (46° to 77° F).<br><br>©2004, 2010, 2013 Novartis<br><br><span class="Bold">9009878-0713<br><br>Alcon<span class="Sup">®</span><br></span>a Novartis company<br><br><span class="Bold">ALCON LABORATORIES, INC. <br></span>Fort Worth, Texas 76134 USA <br>Printed in USA<br><br>LOT:<br><br>EXP.:<br></p>
<div class="Figure"><img alt="carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8268b70f-3f10-48dd-bb24-baaeb27a1325&amp;name=9009878-0713%20Cyclomydril%205mL%20carton.jpg"></div>
<p><span class="Bold">NDC </span>0065-0359-05<br><br><span class="Bold">Alcon</span><br><span class="Bold">Cyclomydril<span class="Sup">®</span><br>(cyclopentolate hydrochloride, phenylephrine hydrochloride ophthalmic solution)<br></span><br>Sterile<span class="Bold"> 5 mL <br></span><br><span class="Bold">Rx Only<br></span><br><span class="Bold">INGREDIENTS: Each mL contains: Actives: </span>cyclopentolate hydrochloride 0.2%, phenylephrine hydrochloride 1%. <span class="Bold">Preservative: </span>benzalkonium chloride 0.01%. <span class="Bold">Inactives: </span>edetate disodium, boric acid, hydrochloric acid and/or sodium carbonate (to adjust pH), purified water.<br><br><span class="Bold">WARNING: </span>Do not touch dropper tip to any surface, as this may contaminate the solution.<br><br><span class="Bold">USUAL DOSAGE: </span>Instill one drop in each eye every five to ten minutes. Read enclosed insert.<br><br><span class="Bold">STORAGE: </span>Store at 8°-25°C (46°-77°F).<br><br>Printed in USA<br>©2004, 2013 Novartis<br><br><span class="Bold">ALCON LABORATORIES, INC. <br></span>Fort Worth, Texas 76134 USA<br><br>LOT:<br><br>EXP.: <br><br><span class="Bold">H12853-0713</span></p>
<div class="Figure"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8268b70f-3f10-48dd-bb24-baaeb27a1325&amp;name=H12853-0713%20Cyclomydril%205mL%20label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYCLOMYDRIL 		
					</strong><br><span class="contentTableReg">cyclopentolate hydrochloride and phenylephrine hydrochloride solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0359</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOPENTOLATE HYDROCHLORIDE</strong> (CYCLOPENTOLATE) </td>
<td class="formItem">CYCLOPENTOLATE HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>PHENYLEPHRINE HYDROCHLORIDE</strong> (PHENYLEPHRINE) </td>
<td class="formItem">PHENYLEPHRINE HYDROCHLORIDE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0359-02</td>
<td class="formItem">2 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0065-0359-05</td>
<td class="formItem">5 mL in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA084300</td>
<td class="formItem">06/30/1958</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Alcon Research Ltd</td>
<td class="formItem"></td>
<td class="formItem">007672236</td>
<td class="formItem">MANUFACTURE(0065-0359)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8ad1177b-cd6b-84c7-3c00-97a1a1c32921</div>
<div>Set id: 8268b70f-3f10-48dd-bb24-baaeb27a1325</div>
<div>Version: 5</div>
<div>Effective Time: 20110803</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
